teverelix

Teverelix is a synthetic decapeptide and gonadotropin-releasing hormone (GnRH) antagonist developed primarily for the treatment of advanced prostate cancer and benign prostatic hyperplasia (BPH). It acts by competitively and reversibly binding to GnRH receptors in the pituitary gland, leading to immediate suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which results in rapid reduction of testosterone production in men and estradiol in women. Teverelix is formulated as a trifluoroacetate salt (TFA), with a unique microcrystal suspension that allows for sustained release after injection. The drug has demonstrated good water solubility, low histamine-releasing potency, favorable injection site tolerance, and a long-acting profile suitable for six-week dosing intervals. It is being developed by Antev Limited for use especially in patients with high cardiovascular risk[1][2][4][5][6][7][8].

Other names

teverelix TFAteverelix trifluoroacetate